LKCWBDHBTVXHDL-RMDFUYIESA-N Amikacin Chemical compound LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 4.UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-trideca-5(13),6,8,11-tetraene-11-carboxylic acid Chemical compound GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 4.239000002260 anti-inflammatory agent Substances 0.000 claims description 9.239000003429 antifungal agent Substances 0.000 claims description 10.GSDSWSVVBLHKDQ-UHFFFAOYSA-N Levofloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 10.239000000194 fatty acid Substances 0.000 claims description 11.235000014113 dietary fatty acids Nutrition 0.000 claims description 11.239000002270 dispersing agent Substances 0.000 claims description 13.239000004094 surface-active agent Substances 0.000 claims description 17.150000003431 steroids Chemical class 0.000 claims description 19.239000003937 drug carrier Substances 0.000 claims description 19. 239000008177 pharmaceutical agent Substances 0.000 claims description 26.239000003242 anti bacterial agent Substances 0.000 claims description 30.206010033072 Otitis externa Diseases 0.000 claims description 33.-1 cholesteryl ester Chemical class 0.000 claims description 41.239000008194 pharmaceutical composition Substances 0.000 claims description 49.239000003795 chemical substances by application Substances 0.000 claims description 71.235000011929 mousse Nutrition 0.000 claims abstract description 46.241000195940 Bryophyta Species 0.000 claims abstract description 46.210000000613 Ear Canal Anatomy 0.000 claims abstract description 60.239000006260 foam Substances 0.000 claims abstract description 113.206010014004 Ear disease Diseases 0.000 title claims abstract description 51.239000000203 mixture Substances 0.000 title claims abstract description 123.Assignors: EILAT, ERAN Application granted granted Critical Publication of US9393242B2 publication Critical patent/US9393242B2/en Status Active legal-status Critical Current Anticipated expiration legal-status Critical Links ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from US53001403P external-priority Application filed by Otic Pharma Ltd filed Critical Otic Pharma Ltd Priority to US13/220,350 priority Critical patent/US9393242B2/en Publication of US20110311462A1 publication Critical patent/US20110311462A1/en Priority to US13/437,680 priority patent/US8940321B2/en Assigned to OTIC PHARMA LTD. Original Assignee Otic Pharma Ltd Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) ( en Inventor Eran Eilat Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Granted Application number US13/220,350 Other versions US9393242B2 Google Patents US20110311462A1 - Compositions for treatment of ear disorders and methods of use thereof US20110311462A1 - Compositions for treatment of ear disorders and methods of use thereof
0 Comments
Leave a Reply. |